Drug intelligence / Profile preview

NNC0247-0829

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Subcutaneous

Overview

NNC0247-0829 is an investigational small molecule drug developed by Novo Nordisk for the treatment of overweight and obesity. It acts as a modulator of growth/differentiation factor 15 (GDF15), a protein involved in appetite regulation and energy balance. The drug is administered via subcutaneous injection and has been evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with overweight or obesity. As of June 2025, it has not received regulatory approval from the US FDA or any other agency[1][2][3][4][5][6].

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on NNC0247-0829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0247-0829.

Explore the full profile